Infliximab in ulcerative colitis.
Böcker
Ulrich
U
Department of Medicine II, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Mannheim, Germany. ulrich.boecker@med.ma.uni.heidelberg.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001323:Autoantibodies / Q000187:drug effects / Q000276:immunology*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab